Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act
Latest Action
Became Public Law No: 118-66.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinson’s Act is a health policy bill from the 118th Congress that was introduced in the House of Representatives. The bill aims to establish a national strategy to address Parkinson’s disease, focusing on research, treatment, and public health initiatives. It was enacted into law as Public Law No: 118-66 on July 2, 2024. However, the bill status is listed as Failed / Expired, indicating that it may not have been fully implemented or reauthorized. Specific details of the bill's provisions and full text are not provided in the available source data.
This bill establishes a national plan to combat Parkinson’s disease and was enacted into law, but lacks detailed publicly available text and summary information for further analysis.
- The bill is focused on health policy, specifically targeting Parkinson’s disease.
- It was passed by the House and became Public Law No: 118-66 on July 2, 2024.
- The bill’s full text and official summary are not available in the provided data, limiting detailed analysis.
['Individuals affected by Parkinson’s disease', 'Health agencies involved in neurological disease research and treatment', 'Medical research organizations focusing on Parkinson’s disease', 'Public health entities engaged in disease prevention and management']
['Lack of publicly available full bill text and summary limits transparency and understanding of implementation details', 'Unclear funding mechanisms and oversight provisions due to missing detailed information', 'The status as Failed / Expired may indicate challenges in reauthorization or sustained implementation']
The bill was introduced and passed during the 118th Congress and became law in mid-2024. It reflects ongoing legislative efforts to address neurological diseases through coordinated national strategies. The absence of detailed public documentation in the source data restricts comprehensive contextual analysis.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased federal coordination and funding for Parkinson’s disease research and treatment programs', 'Possible enhancement of public awareness and education about Parkinson’s disease', 'Secondary impacts on healthcare providers and pharmaceutical research sectors through new guidelines or initiatives']
The absence of an official bill summary and full text in the source data limits the ability to fully assess the bill’s provisions, funding, and oversight mechanisms. Additionally, the conflicting status information (Failed / Expired vs. Became Public Law) warrants further clarification to understand the bill’s current legal and operational standing. Transparency in legislative documentation is critical for public accountability and informed oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.